Drug ID: 1d00000116
Drug Name: Aprepitant
Generic Names: Aprecap | Aprelief | Apretero | Empov | Emend
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category B
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.
Recommended Dose: The recommended dose is 125 mg, 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3.
Recommended In: This medication is an antiemetic, prescribed for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting.
Directions For Use: It comes as a capsule to take by mouth, with or without food.
Storage: Store it at room temperature (20-25°C).
Dosage Forms: Capsule
Side Effects: Body as a Whole - Weakness/fatigue, dizziness, dehydration, abdominal pain and fever.
Gastrointestinal - Nausea, constipation, diarrhea, vomiting, heartburn and stomach discomfort.
ENT - Ringing in the ear.
Blood - Decrease in white blood cells.
Metabolic - Loss of appetite.
Central Nervous System - Headache and sleeplessness.
Respiratory - Hiccups.
In Case of Overdose: No specific information is available on the treatment of overdosage. In the event of overdose, Aprepitant should be discontinued and general supportive treatment and monitoring should be provided. Because of the antiemetic activity of aprepitant, drug-induced emesis may not be effective.
Aprepitant cannot be removed by hemodialysis.
Avoid If: Caution should be exercised in patients with history of nausea or vomiting, liver disease, any allergy, who are taking other medications, during pregnancy and breastfeeding.
It may cause dizziness, do not drive a car or operate machinery while taking this medication.
Avoid alcohol consumption.
Contraindicated in patients who are taking astemizole, cisapride, pimozide, or terfenadine and hypersensitivity.
Drug Interaction: Aprepitant is a substrate for CYP3A4; therefore, coadministration of aprepitant with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of aprepitant. Consequently, concomitant administration of aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution. Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in a 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.
Aprepitant is a substrate for CYP3A4; therefore, coadministration of EMEND with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of aprepitant.
It also interact with drugs like Midazolam, Oral contraceptives, Tolbutamide, Warfarin, Vinorelbine, Docetaxel, Methylprednisolone, Dexamethasone.